What is the price-to-earnings ratio of Altimmune?
The price-earnings ratio of Altimmune is currently -3.38.
Altimmune P/E 2025
Altimmune P/E
-3.38
Ticker
ALT
ISIN
US02155H2004
WKN
A2N5Z6
As of Jan 3, 2025, Altimmune's P/E ratio was -3.38, a -18.16% change from the -4.13 P/E ratio recorded in the previous year.
The Altimmune P/E history
Altimmune Aktienanalyse
What does Altimmune do?
Altimmune Inc is a biopharmaceutical company specializing in the development of immunotherapies. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland, USA. Altimmune ist eines der beliebtesten Unternehmen auf Eulerpool.com.P/E Details
Deciphering Altimmune's P/E Ratio
The Price to Earnings (P/E) Ratio of Altimmune is a vital metric that investors and analysts use to determine the company’s market value relative to its earnings. It is calculated by dividing the current stock price by the earnings per share (EPS). A higher P/E ratio could suggest that investors are expecting higher future growth, while a lower ratio may indicate a potentially undervalued company or lower growth expectations.
Year-to-Year Comparison
Assessing Altimmune's P/E ratio on a yearly basis provides insights into the valuation trends and investor sentiment. An increasing P/E ratio over the years signifies growing investor confidence and expectations for future earnings growth, while a decreasing ratio may reflect concerns over the company's profitability or growth prospects.
Impact on Investments
The P/E ratio of Altimmune is a key consideration for investors aiming to balance risk and reward. A comprehensive analysis of this ratio, in conjunction with other financial indicators, aids investors in making informed decisions regarding buying, holding, or selling the company’s stocks.
Interpreting P/E Ratio Fluctuations
Fluctuations in Altimmune’s P/E ratio can be attributed to various factors including changes in earnings, stock price movements, and shifts in investor expectations. Understanding the underlying reasons for these fluctuations is essential for predicting future stock performance and assessing the company's intrinsic value.
Frequently Asked Questions about Altimmune stock
How has the price-earnings ratio of Altimmune changed compared to last year?
The price-to-earnings ratio of Altimmune has increased by -18.16% fallen (meaning "decreased" or "dropped") compared to last year.
What consequences does a high price-earnings ratio have for investors?
A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.
What does a low price-earnings ratio mean?
A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.
Is the price-earnings ratio of Altimmune high compared to other companies?
Yes, the price-to-earnings ratio of Altimmune is high compared to other companies.
How does an increase in the price-earnings ratio of Altimmune affect the company?
An increase in the price-earnings ratio of Altimmune would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.
How does a reduction in the price-to-earnings ratio of Altimmune affect the company?
A decrease in the price-earnings ratio of Altimmune would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.
What are some factors that influence the price-earnings ratio of Altimmune?
Some factors that influence the price-earnings ratio of Altimmune are the company's growth, financial position, industry development, and the overall economic situation.
How much dividend does Altimmune pay?
Over the past 12 months, Altimmune paid a dividend of 873 USD . This corresponds to a dividend yield of about 12,278.48 %. For the coming 12 months, Altimmune is expected to pay a dividend of 0 USD.
What is the dividend yield of Altimmune?
The current dividend yield of Altimmune is 12,278.48 %.
When does Altimmune pay dividends?
Altimmune pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Altimmune?
Altimmune paid dividends every year for the past 0 years.
What is the dividend of Altimmune?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Altimmune located?
Altimmune is assigned to the 'Health' sector.
Wann musste ich die Aktien von Altimmune kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Altimmune from 2/3/2017 amounting to 2.91 USD, you needed to have the stock in your portfolio before the ex-date on 2/6/2017.
When did Altimmune pay the last dividend?
The last dividend was paid out on 2/3/2017.
What was the dividend of Altimmune in the year 2024?
In the year 2024, Altimmune distributed 0 USD as dividends.
In which currency does Altimmune pay out the dividend?
The dividends of Altimmune are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Altimmune
Our stock analysis for Altimmune Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Altimmune Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
